BLIS Technologies (BLT.NZ) Osake Kurssi
BLIS Technologies Kurssi
Liikevaihto on kasvanut 17,6 % vuodessa viimeisten 19 vuoden aikana 12,64 M NZD:een. Osakekohtainen tulos on kasvanut 11,3 % vuodessa viimeisten 6 vuoden aikana. BLIS Technologiesn nettomarginaali on nyt 6,6 %, noussut 5,3 %:sta muutama vuosi sitten. BLIS Technologiesn osinkotuotto on tällä hetkellä noin 2,00 %.
BLIS Technologies osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
BLIS Technologies liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset BLIS Technologies -osakkeesta
BLIS Technologies Ltd. operates on a business model focused on developing and commercializing advanced probiotic products. Specializing in oral probiotics, the company aims to enhance oral health by harnessing the natural antimicrobial properties of certain strains of bacteria. BLIS Technologies Ltd. utilizes cutting-edge research and development to create innovative probiotic formulations. With a primary focus on streptococcus salivarius, their products offer targeted solutions for various oral concerns, including bad breath and sore throats. By leveraging their expertise in probiotics, BLIS Technologies Ltd. aims to improve oral hygiene and overall well-being through their unique business model.
BLIS Technologies Ltd is primarily active in the health and wellness industry.
The main competitors of BLIS Technologies Ltd in the market include other companies that specialize in probiotics and oral health solutions. Some notable competitors include Probi AB, a Swedish biotechnology company; BioGaia AB, a Swedish healthcare company; and DuPont Nutrition & Biosciences, a global leader in probiotics. These companies offer similar products and services, targeting the same consumer base as BLIS Technologies Ltd.
BLIS Technologies Ltd is a renowned company with a rich history and background. Founded in 2000, BLIS Technologies specializes in advanced probiotics research and development. The company focuses on creating innovative oral probiotic products that support oral and upper respiratory health. BLIS Technologies has gained recognition for its groundbreaking work in the field of bacteriocin-producing probiotics. With a team of dedicated researchers and scientists, the company continues to push boundaries and deliver high-quality products that promote overall well-being. BLIS Technologies is committed to staying at the forefront of probiotics technology, improving lives through its science-backed solutions.
BLIS Technologies Ltd has achieved several significant milestones. The company pioneered the development of advanced oral probiotics, which have gained recognition worldwide. BLIS has successfully commercialized its proprietary BLIS K12 bacteria strain, which is proven to promote oral health and prevent throat infections. Additionally, BLIS Technologies Ltd has made substantial progress in expanding its product portfolio, introducing innovative oral care solutions for different age groups. With a strong focus on research and development, BLIS continues to advance its probiotics technology, ensuring the delivery of safe and effective products. The company’s commitment to promoting oral health has positioned BLIS Technologies Ltd as a leader in the probiotics industry.
BLIS Technologies Ltd is primarily present in New Zealand and Australia.
BLIS Technologies Ltd represents the values of innovation, research excellence, and dedication to improving oral health. With a corporate philosophy focused on developing and commercializing unique probiotic strains, BLIS Technologies aims to provide effective and natural solutions for maintaining oral wellness. Their commitment to pioneering advancements in probiotic technology has allowed them to establish a strong market presence and deliver quality products. By prioritizing customer satisfaction and delivering scientifically proven solutions, BLIS Technologies Ltd has become a trusted name in the industry, continually striving to improve oral health and overall well-being.
Nykyisellä valuuttakurssilla BLIS Technologies-osake noteerataan hintaan 0,01 EUR (0,03 NZD).
BLIS Technologies Ltd is an innovative company specializing in the development of personal oral health care and technologies. The company has two business areas - oral health care and technologies. In the field of oral health care, the company offers a wide range of products that build upon the body's natural defense mechanisms to keep the mouth healthy. BLIS Probiotics is a key player in the market by producing a unique type of probiotic bacteria specifically designed for mouth protection. The company offers BLIS K12 Breath Gum, which contains unique probiotics that target bacterial infections in the oral cavity. These gums reduce tooth decay and combat the causes of halitosis. Another important brand of BLIS is Throat Guard Probiotics. These lozenges are specially formulated to reduce sore throats and upper respiratory infections, and soothe the throat. They are available in various flavors and can be used by adults and children alike. In addition to oral health products, BLIS Technologies also produces technologies for monitoring and analyzing bacterial strains. The company has developed a method for identifying strains of bacteria that often reside in the human body, such as Streptococcus mutans, Lactobacillus fermentum, and Staphylococcus aureus. With this technology, it is possible to obtain real-time information about bacterial strains and analyze their genetic profiles. BLIS Technologies also sells licenses for its technologies to other companies and organizations in the food and beverage industry. These companies can enhance their own products using BLIS technologies and leverage the benefits of probiotics to improve consumer health. The company works closely with customers around the world to develop customized solutions for their specific requirements. Customers form partnerships with BLIS Technologies to enhance their products and promote the health of their customers. Overall, BLIS Technologies is a leading provider of probiotic technologies and oral health products. The company is continuously striving to develop innovative solutions to improve people's health. By producing high-quality probiotics and providing services for monitoring and analyzing bacterial strains, BLIS Technologies has become a significant player in the industry.
Liikevaihtoa ei voida laskea BLIS Technologies:lle tällä hetkellä.
Voittoa ei voida laskea BLIS Technologies:lle tällä hetkellä.
P/E-suhdetta ei voida laskea BLIS Technologies:lle tällä hetkellä.
P/S-suhdetta ei voida laskea BLIS Technologies:lle tällä hetkellä.
BLIS Technologies:n Eulpool-laatuscore on 6/10.
BLIS Technologies:n ISIN on NZBLTE0002S8. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
BLIS Technologies:n WKN on 724615. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
BLIS Technologies:n ticker on BLT.NZ. Tämä pörssinoteeraus käytetään BLIS Technologies-osakkeiden kauppaan pörssissä.
BLIS Technologies osake
BLIS Technologies vertaisryhmä
BLIS Technologies Ticker
BLIS Technologies FIGI
Kaikki tunnusluvut ja syvällinen analyysi BLIS Technologies:sta
Meidän osakeanalyysimme BLIS Technologies-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut BLIS Technologies:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: